B cells and antibodies in multiple sclerosis pathogenesis and therapy

Area of Science:

• Neuroimmunology
• Immunology

Background:

• B cells and antibodies, particularly oligoclonal bands, are prominent diagnostic markers in multiple sclerosis (MS).
• The central nervous system (CNS) supports B-cell activity and local antibody production, contributing to MS pathogenesis.
• B cells can modulate CNS inflammation, with evidence suggesting a predominantly pro-inflammatory role in many MS patients.

Purpose of the Study:

• To review B-cell biology and their role in CNS inflammation in MS.
• To summarize current efforts in identifying pathogenic antibody targets in MS.
• To discuss the impact of various MS therapies on B-cell immunology.

Main Methods:

• Literature review of B-cell biology, MS pathogenesis, and therapeutic interventions.
• Analysis of immunodiagnostic features and CNS-specific B-cell factors.
• Summary of clinical trial data and mechanistic studies on MS treatments.

Main Results:

• B cells and antibodies are integral to MS immunopathology, with the CNS acting as a site for local antibody production.
• B-cell depletion emerges as a significant therapeutic strategy.
• Approved and investigational MS therapies demonstrate diverse effects on B-cell populations and function.

Conclusions:

• Understanding B-cell roles in MS is crucial for developing targeted therapies.
• Modulating B-cell activity represents a key therapeutic avenue in multiple sclerosis.
• Further research is needed to identify specific pathogenic antibody targets in MS.